20th May 2022 | Pharma Updates

PharmaState Updates – Latest Pharma Happenings

Gautam Adani focuses on the health industry and establishes division for it

Adani Enterprises has established a 100% subsidiary, Adani Health Ventures, to manage medical and diagnostic laboratories, research centres, and other healthcare-related activities in India.

As per Cipla's Samina Hamied and Umang Vohra, "Caring for patients is in our DNA"

Cipla was at the forefront of the pharmaceutical industry’s response to the Covid-19 pandemic, whether it was by partnering with MNCs for products like remdesivir or tocilizumab, or by ramping up production of more common but still necessary drugs.

Gynica and HempStreet announced strategic partnership

HempStreet has collaborated with Gynica, an Israeli R&D firm dedicated to changing the culture of gynaecological treatment through clinically proven, cannabinoid-based solutions.

Dera Bassi pharma firm fined ₹5 lakh for violating the Water Act

The Punjab Pollution Control Board (PPCB) fined a pharmaceutical company based in Dera Bassi 5 lakh for multiple violations of the Water (Prevention and Control of Pollution) Act.

Dr. Reddy's Labs Q4 PAT falls 76% due to pricing pressure and a lack of export benefit

Dr. Reddy’s Laboratories (DRL) of Hyderabad reported a 76% year-on-year (YoY) decline in profit after tax (PAT) to Rs 88 crore in Q4FY22, owing to pricing pressure in North America and Europe, lower export benefits, and an increase in inventory provisions.

Jardiance from Boehringer Ingelheim approved by the CDSCO to treat a new heart failure indication

Jardiance, BI’s best-selling drug in India, and used to treat type 2 diabetes and heart failure with a low ejection fraction (HFrEF). CDSCO recently granted approval for the treatment of heart failure with preserved ejection fraction (HFpEF).

Zealand Pharma plans to apply for FDA approval of its treatment for a rare genetic disorder in infants

Dasiglucagon is being tested as a treatment for children with congenital hyperinsulinism, and based on data from Phase 3 clinical trial, the company plans to discuss submitting a new drug application to the FDA.